Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,798,550
  • Shares Outstanding, K 333,250
  • Annual Sales, $ 135,070 K
  • Annual Income, $ -384,730 K
  • 60-Month Beta N/A
  • Price/Sales 43.15
  • Price/Cash Flow N/A
  • Price/Book 4.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.53 +32.37%
on 10/15/19
18.10 -1.05%
on 11/12/19
+3.85 (+27.43%)
since 10/11/19
3-Month
12.47 +43.62%
on 08/15/19
18.48 -3.08%
on 09/23/19
+4.89 (+37.56%)
since 08/12/19

Most Recent Stories

More News
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 89.23 (+0.68%)
AXLA : 3.53 (-16.35%)
DNLI : 14.99 (+0.94%)
EVLO : 6.51 (+1.88%)
KLDO : 6.11 (-1.29%)
MRNA : 18.03 (+3.62%)
RUBY : 10.19 (-6.94%)
MCRB : 3.64 (-1.10%)
SYRS : 5.00 (+0.20%)
Top Ranked Momentum Stocks to Buy for November 8th

Top Ranked Momentum Stocks to Buy for November 8th

MRNA : 18.03 (+3.62%)
INMD : 43.88 (-3.37%)
EVER : 29.20 (-5.90%)
CYBE : 18.35 (+0.60%)
Moderna: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Moderna Inc. (MRNA) on Wednesday reported a loss of $123.2 million in its third quarter.

MRNA : 18.03 (+3.62%)
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results

--Positive interim results announced from Phase 1 mRNA encoding chikungunya antibody (mRNA-1944) study

MRNA : 18.03 (+3.62%)
Moderna to Present at Credit Suisse 28th Annual Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 18.03 (+3.62%)
Moderna Named Top Employer by Science for Fifth Consecutive Year

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 18.03 (+3.62%)
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

--mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia)

MRNA : 18.03 (+3.62%)
Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

MRNA : 18.03 (+3.62%)
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

--Zika: Preclinical data show Zika vaccine (mRNA-1893) protective against Zika virus transmission during pregnancy in mice; mRNA-1893 is currently being evaluated in a Phase 1 study

MRNA : 18.03 (+3.62%)
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)

--mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus)

MRNA : 18.03 (+3.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRNA with:

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

2nd Resistance Point 17.69
1st Resistance Point 17.55
Last Price 18.03
1st Support Level 17.23
2nd Support Level 17.05

See More

52-Week High 29.79
Fibonacci 61.8% 22.82
Fibonacci 50% 20.67
Fibonacci 38.2% 18.51
Last Price 18.03
52-Week Low 11.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar